Back

COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid.

Heili-Frades, S.; Minguez, P.; Mahillo-Fernandez, I.; Prieto-Rumeau, T.; Herrero Gonzalez, A.; de la Fuente, L.; Rodriguez Nieto, M. J.; Peces-Barba Romero, G.; Peces-Barba, M.; Carballosa de Miguel, M. d. P.; Fernandez Ormaechea, I.; Naya Prieto, A.; Ezzine de Blas, F.; Jimenez Hiscock, L.; Perez Calvo, C.; Santos, A.; Munoz Alameda, L. E.; Romero Bueno, F.; Hernandez-Mora, M. G.; Cabello Ubeda, A.; Alvarez Alvarez, B.; Petkova, E.; Carrasco, N.; Martin Rios, D.; Gonzalez Mangado, N.; Sanchez Pernaute, O.

2020-05-29 respiratory medicine
10.1101/2020.05.22.20109850 medRxiv
Show abstract

There is limited information describing features and outcomes of patients requiring hospitalization for COVID19 disease and still no treatments have clearly demonstrated efficacy. Demographics and clinical variables on admission, as well as laboratory markers and therapeutic interventions were extracted from electronic Clinical Records (eCR) in 4712 SARS-CoV2 infected patients attending 4 public Hospitals in Madrid. Patients were stratified according to age and stage of severity. Using multivariate logistic regression analysis, cut-off points that best discriminated mortality were obtained for each of the studied variables. Principal components analysis and a neural network (NN) algorithm were applied. A high mortality incidence associated to age >70, comorbidities (hypertension, neurological disorders and diabetes), altered vitals such as fever, heart rhythm disturbances or elevated systolic blood pressure, and alterations in several laboratory tests. Remarkably, analysis of therapeutic options either taken individually or in combination drew a universal relationship between the use of Cyclosporine A and better outcomes as also a benefit of tocilizumab and/or corticosteroids in critically ill patients. We present a large Spanish population-based study addressing factors influencing survival in current SARS CoV2 pandemic, with particular emphasis on the effectivity of treatments. In addition, we have generated an NN capable of identifying severity predictors of SARS CoV2. A rapid extraction and management of data protocol from eCR and artificial intelligence in-house implementations allowed us to perform almost real time monitoring of the outbreak evolution.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 0.1%
26.8%
2
Communications Medicine
85 papers in training set
Top 0.1%
10.5%
3
Frontiers in Medicine
113 papers in training set
Top 0.2%
10.5%
4
Infection
15 papers in training set
Top 0.1%
6.6%
50% of probability mass above
5
Journal of Medical Virology
137 papers in training set
Top 0.5%
5.0%
6
Life
27 papers in training set
Top 0.1%
4.1%
7
Journal of Clinical Medicine
91 papers in training set
Top 1%
3.7%
8
PLOS ONE
4510 papers in training set
Top 37%
3.7%
9
Viruses
318 papers in training set
Top 2%
2.0%
10
Clinical and Translational Medicine
30 papers in training set
Top 0.2%
2.0%
11
International Journal of Environmental Research and Public Health
124 papers in training set
Top 4%
1.5%
12
European Respiratory Journal
54 papers in training set
Top 1%
1.3%
13
Frontiers in Molecular Biosciences
100 papers in training set
Top 3%
1.0%
14
Peer Community Journal
254 papers in training set
Top 3%
0.9%
15
eBioMedicine
130 papers in training set
Top 3%
0.9%
16
Annals of Clinical and Translational Neurology
29 papers in training set
Top 1%
0.8%
17
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.8%
18
Clinical Microbiology and Infection
60 papers in training set
Top 1%
0.8%
19
Journal of Medical Internet Research
85 papers in training set
Top 5%
0.7%
20
iScience
1063 papers in training set
Top 36%
0.7%
21
Leukemia
39 papers in training set
Top 0.8%
0.7%
22
Epidemiology and Infection
84 papers in training set
Top 4%
0.5%
23
Journal of Clinical Virology
62 papers in training set
Top 1%
0.5%
24
Swiss Medical Weekly
12 papers in training set
Top 0.4%
0.5%
25
ERJ Open Research
44 papers in training set
Top 1%
0.5%
26
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.5%
27
Genomics
60 papers in training set
Top 3%
0.5%